Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Sell Biotheranostics Cancer Test

NEW YORK (GenomeWeb News) - Molecular diagnostic test maker BioTheranostics said today that Lab21 will market and sell one of its cancer tests in the UK, Ireland, and in Middle East countries.

The BioMerieux subsidiary said that the two-year commercialization agreement covers its Theros CancerType ID cancer classifier test. The 92-gene test identifies 39 types of tumors and 64 sub-types, and is used to help doctors guide their treatment decisions for cancer patients whose tumor sites are uncertain or unknown.

"The partnership with Lab21 represents the successful transition to our second generation molecular cancer classification technology in Europe," Biotheranostics CEO Richard Ding said in a statement. "This RT-PCR based test will replace our micro-array based assay, which was licensed to Agendia in Europe."

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.